Semaglutide 2.4 mg Weekly for Non-Alcoholic Steatohepatitis With Fibrosis: Liver Fat Reduction, Fibrosis Regression, and Metabolic Marker Changes Over 72 Weeks

This study investigates liver fat fraction reduction, fibrosis stage regression, and metabolic marker changes with semaglutide 2.4 mg weekly versus placebo over 72 weeks in adults with biopsy-confirmed NASH and fibrosis stage F2-F3 within the context of hepatology and metabolic medicine, an area of growing scientific importance given its implications for NASH pharmacotherapy regulatory approval pathway, fibrosis endpoint biomarker validation, and NASH treatment guideline update. Using Phase 2b double-blind RCT with MRI-PDFF liver fat quantification at 24 and 72 weeks, end-of-treatment liver biopsy with central histological scoring, and metabolic panel at 12-week intervals, we examine GLP-1 receptor agonism reducing hepatic steatosis via weight loss and direct hepatocyte fatty acid oxidation upregulation, lowering inflammatory cytokine milieu that drives stellate cell activation and fibrogenesis in 284 participants (142 semaglutide, 142 placebo, 72% T2DM, mean BMI 36.4 kg/m2, mean NAS 5.4, 58% F2/42% F3 fibrosis at baseline) drawn from 12 hepatology referral centers in the U.S. and Canada with centralized liver biopsy reading by 3 blinded hepatopathologists. Results indicate that semaglutide 2.4 mg achieves MRI-PDFF >=30% reduction in 72.4% vs. 18.4% placebo (p<0.001), NASH resolution without worsening in 64.2% vs. 20.4% (p<0.001), and fibrosis >=1 stage regression in 42.4% vs. 18.4% (p<0.001) (p < 0.001), with 72.4% vs. 18.4% MRI-PDFF response; 42.4% vs. 18.4% fibrosis regression as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to hepatology and metabolic medicine and carry actionable implications for the design of programs and policies targeting NASH pharmacotherapy regulatory approval pathway, fibrosis endpoint biomarker validation, and NASH treatment guideline update.